Analyst Report: COO

1. EXECUTIVE SUMMARY

Over the weekly trading period ending September 16, 2026, The Cooper Companies, Inc. (NASDAQ: COO) plummeted by -13.97%, closing at $53.91 on September 16 after hitting a 52-week low of $51.01. The sharp selloff was triggered by a "double whammy" in the company's fiscal Q3 2026 earnings release on September 9, 2026: a top-line revenue miss coupled with a steep guidance reduction for Q4 and full-year FY2026 due to proactive U.S. channel inventory destocking, alongside the board’s unexpected decision to terminate its multi-month strategic review and retain its CooperSurgical business unit rather than pursue a sale or spinoff. The news abruptly dismantled the M&A takeout premium that had supported the stock, prompting a wave of Wall Street analyst downgrades and shareholder litigation investigations. Despite operational headwinds in channel distribution, the core business generated record quarterly free cash flow of $273 million, delivered its 11th consecutive non-GAAP EPS beat, expanded its share buyback authorization to $3 billion, and triggered substantial open-market insider buying by board members at ~$54. The decline represents a severe valuation reset following a guidance cut and broken M&A thesis rather than a collapse in fundamental solvency.

2. THE CATALYST (CRITICAL)

Specific Triggering Events

1. Fiscal Q3 2026 Revenue Miss & Guidance Cut:

   • Q3 Revenue: Reported $1.066 billion (+1% YoY, +1% organic), missing Wall Street consensus estimates of $1.098B – $1.100B.
   • Q3 EPS: Non-GAAP diluted EPS came in at $1.15 (+4% YoY), beating consensus estimates of $1.12. GAAP EPS rose to $2.24 (vs. $0.49 in Q3 FY25), aided by a $307.2 million discrete tax settlement from a U.K. tax examination.
   • Q4 FY26 Guidance Cut: Guided Q4 EPS to $1.05 – $1.09 vs. analyst consensus of $1.19, with Q4 revenue of $1.057B – $1.080B vs. $1.106B expected.
   • Full-Year FY26 Guidance Cut: Reduced full-year non-GAAP EPS to $4.51 – $4.55 (prior guidance was $4.58 – $4.66) vs. consensus of $4.63. Lowered full-year revenue guidance to $4.229B – $4.252B vs. consensus of $4.300B.
   • Driver of Miss: Management disclosed a deliberate reduction in U.S. distributor channel inventory within CooperVision (Americas revenue down 2% organically; legacy hydrogel lenses down double-digits across the board), accompanied by persistent demand softness in the Asia-Pacific region (-5% organic). CEO Al White signaled that distributor destocking will continue to weigh on Q4 performance.

2. Termination of Strategic Review (Sale of CooperSurgical Off the Table):

   • The Board of Directors completed its strategic review (initiated in December 2025) and unanimously concluded that retaining CooperSurgical creates higher long-term shareholder value than selling or spinning off the unit.
   • This decision crushed months of takeover/divestiture speculation that had provided a valuation floor. To offset the impact, the Board increased its share repurchase program authorization from $2.0 billion to $3.0 billion.

3. Analyst Downgrades & Target Price Cuts (Sept 10–11, 2026):

   • William Blair: Downgraded COO from Outperform to Market Perform.
   • BofA Securities: Downgraded from Buy to Neutral and cut price target to $65.
   • Stifel: Cut price target from $85 to $70 (Buy).
   • Needham: Slashed price target from $86 to $73 (Buy).
   • Wells Fargo: Cut price target from $66 to $61 (Equal Weight).

4. Shareholder Lawsuits / Regulatory Scrutiny:

   • On September 11–15, 2026, multiple national investor rights law firms (Hagens Berman, Levi & Korsinsky, Law Offices of Howard G. Smith) announced investigations into potential securities fraud. The inquiries center on whether management’s optimistic Q2 statements (June 4, 2026) regarding channel demand misled investors prior to disclosing inventory destocking in Q3.

Event Timeline & Sources

• Wednesday, Sept 9, 2026 (4:05 PM EDT): Q3 FY26 earnings release and strategic review conclusion announced. COO dropped -15.96% in after-hours trading.
• Thursday, Sept 10, 2026: Regular market session opened with COO plunging -14.6% to -15.0% to close at $54.17.
• Monday, Sept 14, 2026: Form 4 SEC filings disclosed significant open-market insider buying by board members.

3. COMPANY PROFILE

Core Operations

The Cooper Companies, Inc. (NASDAQ: COO) is a global medical device manufacturer organized into two main operating units:

1. CooperVision: Develops, manufactures, and markets contact lenses (spherical, toric, multifocal, and specialty designs). Flagship brands include MyDay, Biofinity, Clariti, and MiSight (myopia control). CooperVision commands ~25% of the U.S. contact lens market.
2. CooperSurgical: Focuses on fertility, IVF solutions, surgical products, and women's healthcare. Products cover the full IVF cycle, as well as Paragard—the only hormone-free IUD in the U.S. (17% market share).

Key Financial & Market Metrics (As of September 16, 2026)

4. DEEP DIVE ANALYSIS

Pre-Earnings Stock Price (Sept 8):   ~$67.69  |  Peak 52-Wk: $89.83
Post-Earnings Gap Down (Sept 10):    ~$53.35 - $54.17
Current Price (Sept 16):             ~$53.91  |  Weekly Decline: -13.97%

Fundamentals: Justified Reset vs. Market Overreaction

The -13.97% weekly crash reflects two distinct mechanisms:

1. A Fundamentals & Guidance Reset: U.S. distributor channel inventory destocking directly reduces near-term top-line sales without reflecting an underlying loss of consumer adoption. Management noted that end-user consumption of daily silicone hydrogel lenses (MyDay) continues to grow at double-digit rates in EMEA and the Americas. However, channel destocking directly hits quarterly revenue recognition.
2. Devaluation of M&A Multiple: Shares had accumulated an M&A premium since December 2025 due to rumors of a lucrative CooperSurgical sale. When the board retained the segment, that premium evaporated instantly.

However, the selloff appears oversold relative to underlying cash flow:

• Record Cash Generation: Free cash flow reached a record $273.0 million in Q3 (+66% YoY).
• Operating Leverage: Non-GAAP gross margins remained solid at 67%, and the balance sheet features manageable leverage with a Debt-to-Equity ratio of 0.23x.

Strong Insider Conviction Signal

Following the drop, key board members made open-market share purchases:

• Director Lawrence Kurzius: Purchased 10,000 shares on Sept 14, 2026, at an average price of $53.915 ($539,150 total execution value), expanding his total holding by 90.1%.
• Director Walter Rosebrough, Jr.: Purchased 3,000 shares on Sept 14, 2026, at $54.29 per share ($162,870 total value), increasing his stake by 17.6%.
• Total insider transactions over the past 12 months show 10 buys and 0 sells, indicating internal confidence in long-term valuation.

Bull Case vs. Bear Case

5. TECHNICAL SNAPSHOT

Resistance 2: $70.00 - $71.25 (50-day Moving Average)
Resistance 1: $63.50 - $65.00 (Pre-Earnings Breakdown Level)
------------------------------------------------------------------
CURRENT PRICE: $53.91 (As of Sept 16 Close)
------------------------------------------------------------------
Support 1:    $51.01 - $51.76 (52-Week Low / Post-Earnings Low)
Support 2:    $50.00 (Psychological / Multi-Year Level)

• Price Action & Breakdown: COO suffered a severe gap-down on Sept 10, breaking below its previous 52-week support of $58.89 down to $51.01.
• Volume Analysis: The initial drop occurred on massive capitulation volume—6.4M to 8.38M shares traded on Sept 9–10 vs. a 90-day average daily volume of 2.3M – 2.5M shares. Volume has since normalized to ~4.4M shares during consolidation.
• Technical Trend: The stock sits deeply oversold on RSI indicators, establishing a tight bottoming range between $52.50 and $55.00 supported by institutional and insider accumulation.

6. RISK FACTORS

1. Protracted Channel Inventory Adjustments: Management expects destocking to weigh on Q4 2026 results. If optical distributors continue trimming inventory into Q1 FY2027, top-line recovery will be delayed.
2. Asia-Pacific Regional Softness: APAC organic revenues fell 5% in Q3. Macroeconomic headwinds or intensified price competition from local players (e.g., Menicon, Seed) could constrain global margins.
3. Class-Action Litigation Exposure: Pending law firm investigations regarding the timing of U.S. channel disclosures could result in formal class-action lawsuits.
4. Fertility Segment Volatility: While CooperSurgical revenue grew 3% organically in Q3, past product recalls (embryo culture media) continue to generate legal accruals that distort GAAP profitability.

7. ACTIONABLE OUTLOOK

Short-Term (1–2 Weeks): Range-Bound Consolidation

Expect price action to consolidate within the $51.50 – $56.00 range. High-volume insider buying at $53.91 provides a floor against further immediate panic selling. Technical relief bounces may retest $57.00–$59.00, but gains will likely be capped by overhead supply from broken technical support.

Medium-Term (1–3 Months): Awaiting Q4 Inventory Normalization

Medium-term price performance will be driven by the Q4 FY2026 earnings release (expected early December 2026). Key metrics to monitor:

• Whether CooperVision U.S. organic growth stabilizes as distributor inventory normalizes.
• Execution pace of the newly expanded $3.0 billion share repurchase plan.
• Re-establishment of FY2027 organic growth guidance near historic 5%–7% targets.

Long-Term Thesis: Fundamental Value intact at ~12x Forward Earnings

While the loss of M&A optionality for CooperSurgical disappointed event-driven traders, the structural core thesis for COO remains sound. CooperVision continues to hold a duopoly-like position alongside Alcon and Johnson & Johnson in premium daily silicone hydrogel lenses and myopia control (MiSight). With record free cash flow ($273M/quarter), strong balance sheet liquidity, a forward P/E multiple compressed to historic lows (~12x), and active insider buying, long-term institutional investors have an attractive entry point for high-quality medtech exposure.